Faculty Bibliography
Searched for:
person:nowaka01
in-biosketch:true
Total Results:
193
EAACI Molecular Allergology User's Guide 2.0
Since the discovery of immunoglobulin E (IgE) as a mediator of allergic diseases in 1967, our knowledge about the immunological mechanisms of IgE-mediated allergies has remarkably increased. In addition to understanding the immune response and clinical symptoms, allergy diagnosis and management depend strongly on the precise identification of the elicitors of the IgE-mediated allergic reaction. In the past four decades, innovations in bioscience and technology have facilitated the identification and production of well-defined, highly pure molecules for component-resolved diagnosis (CRD), allowing a personalized diagnosis and management of the allergic disease for individual patients. The first edition of the "EAACI Molecular Allergology User's Guide" (MAUG) in 2016 rapidly became a key reference for clinicians, scientists, and interested readers with a background in allergology, immunology, biology, and medicine. Nevertheless, the field of molecular allergology is moving fast, and after 6 years, a new EAACI Taskforce was established to provide an updated document. The Molecular Allergology User's Guide 2.0 summarizes state-of-the-art information on allergen molecules, their clinical relevance, and their application in diagnostic algorithms for clinical practice. It is designed for both, clinicians and scientists, guiding health care professionals through the overwhelming list of different allergen molecules available for testing. Further, it provides diagnostic algorithms on the clinical relevance of allergenic molecules and gives an overview of their biology, the basic mechanisms of test formats, and the application of tests to measure allergen exposure.
PMID: 37186333
ISSN: 1399-3038
CID: 5503492
Cow's milk formula each day may keep milk allergy away [Comment]
PMID: 36737157
ISSN: 1534-4436
CID: 5426812
Journal of allergy & clinical immunology. In practice. 2023:11(1):326-328.DOI: 10.1016/j.jaip.2022.10.029
Recurrence of Food Protein-Induced Enterocolitis Syndrome (FPIES) Following a Food Challenge [Editorial]
PMID: 36610758
ISSN: 2213-2201
CID: 5410222
Berberine-containing natural-medicine with boiled peanut-OIT induces sustained peanut-tolerance associated with distinct microbiota signature
BACKGROUND:Gut microbiota influence food allergy. We showed that the natural compound berberine reduces IgE and others reported that BBR alters gut microbiota implying a potential role for microbiota changes in BBR function. OBJECTIVE:We sought to evaluate an oral Berberine-containing natural medicine with a boiled peanut oral immunotherapy (BNP) regimen as a treatment for food allergy using a murine model and to explore the correlation of treatment-induced changes in gut microbiota with therapeutic outcomes. METHODS:B cells were assessed by flow cytometry. Fecal pellets were used for sequencing of bacterial 16S rDNA by Illumina MiSeq. Sequencing data were analyzed using built-in analysis platforms. RESULTS:were negatively correlated. CONCLUSIONS:BNP is a promising regimen for food allergy treatment and its benefits in a murine model are associated with a distinct microbiota signature.
PMCID:10415201
PMID: 37575233
ISSN: 1664-3224
CID: 5595472
Journal of allergy & clinical immunology. In practice. 2022:10(12):3328-3332.e2.DOI: 10.1016/j.jaip.2022.08.055
Educational resources received by families after successful baked egg/baked milk oral food challenge: An international survey
PMID: 36184022
ISSN: 2213-2201
CID: 5361432
Journal of allergy & clinical immunology. In practice. 2022:10(12):3339-3340.e10.DOI: 10.1016/j.jaip.2022.09.037
A 2-Month-Old Child With Hypovolemic Shock
PMID: 36496216
ISSN: 2213-2201
CID: 5381752
Updated threshold dose-distribution data for sesame [Letter]
PMID: 35531634
ISSN: 1398-9995
CID: 5214082
Defining socioeconomic and racial disparities in food allergy: The time is now [Editorial]
PMID: 36155692
ISSN: 1534-4436
CID: 5333942
Diagnosis and management of food allergy-associated gastroesophageal reflux disease in young children-EAACI position paper
Gastro-oesophageal reflux (GOR) and food allergy (FA) are common conditions, especially during the first 12 months of life. When GOR leads to troublesome symptoms, that affect the daily functioning of the infant and family, it is referred to as GOR disease (GORD). The role of food allergens as a cause of GORD remains controversial. This European Academy of Allergy and Clinical Immunology (EAACI) position paper aims to review the evidence for FA-associated GORD in young children and translate this into clinical practice that guides healthcare professionals through the diagnosis of suspected FA-associated GORD and medical and dietary management. The task force (TF) on non-IgE mediated allergy consists of EAACI experts in paediatric gastroenterology, allergy, dietetics and psychology from Europe, United Kingdom, United States, Turkey and Brazil. Six clinical questions were formulated, amended and approved by the TF to guide this publication. A systematic literature search using PubMed, Cochrane and EMBASE databases (until June 2021) using predefined inclusion criteria based on the 6 questions was used. The TF also gained access to the database from the European Society of Paediatric Gastroenterology and Hepatology working group, who published guidelines on GORD and ensured that all publications used within that position paper were included. For each of the 6 questions, practice points were formulated, followed by a modified Delphi method consisting of anonymous web-based voting that was repeated with modified practice points where required, until at least 80% consensus for each practice point was achieved. This TF position paper shares the process, the discussion and consensus on all practice points on FA-associated GORD.
PMID: 36282131
ISSN: 1399-3038
CID: 5359092
Journal of allergy & clinical immunology. In practice. 2022:10(9):2274-2279.DOI: 10.1016/j.jaip.2022.04.040
Acute At-Home Management of Anaphylaxis: 911: What Is the Emergency?
The appropriate at-home management of anaphylaxis begins with patient education on recognition and treatment, especially when and how to use epinephrine. Delayed administration of epinephrine as well as having severe symptoms and needing multiple doses of epinephrine to treat symptoms are risk factors for biphasic anaphylaxis. The successful implementation of at-home management of anaphylaxis requires appropriate patient selection and an algorithmic approach that recommends activation of emergency medical services (EMS) when the patient does not adequately respond to at-home administration of epinephrine or there are extenuating patient-related circumstances. Fortunately, approximately 98% of anaphylactic episodes respond to 2 or fewer doses of epinephrine, the standard prescription used for epinephrine autoinjectors; fatal anaphylaxis is very rare, as low as 0.002 deaths/million person-years; and biphasic reactions are uncommon (∼5%), and only extremely rarely lethal. Thus, most common concerns leading to recommended EMS activation and emergency department visits after epinephrine administration are generally unsubstantiated. Furthermore, emergency department visits do not always lead to better treatment and drive health care costs higher. Open communications with patients and families regarding risks and benefits of at-home management and observation versus EMS activation and emergency department evaluation after epinephrine administration for anaphylaxis are essential. However, we believe the data indicate that it is time to reconsider the often used and taught approach that recommends EMS activation whenever epinephrine is used.
PMID: 35569813
ISSN: 2213-2201
CID: 5284142
